Post-transplant lymphoproliferative disease
MONDO:0019088Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)
Also known as: PTLD, post-transplant lymphoproliferative disorder
31 clinical trials for this condition and its sub-types, 28 tagged with Post-transplant lymphoproliferative disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New cell therapy targets Epstein-Barr virus in immune-compromised patients
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain lymphomas and post-transplant complications. The treatment uses specially prepared immune cells to fight the virus. The main go…
Phase 2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug cocktail aims to spare transplant patients from chemo
Disease control OngoingThis study tests a combination of two drugs, polatuzumab vedotin and rituximab, as a first treatment for a rare cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ or stem cell transplant. The goal is to see if this combo is safe and ef…
Phase 1/2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug targets virus to fight rare cancer
Disease control OngoingThis phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered T-Cells take on tough lymphoma in early trial
Disease control OngoingThis phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on recurrent B-Cell cancers
Disease control OngoingThis early-stage trial tests a new cellular immunotherapy for adults with certain B-cell cancers (like lymphomas and leukemias) that have come back. Researchers take a patient's own white blood cells, modify them in the lab to better recognize and attack cancer cells, and infuse …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
AI chest X-Rays could catch hidden lung disease in zambia
Diagnosis OngoingThis project tests an integrated approach to lung health in Zambia. Community and primary care clinics screen people with cough, breathlessness or other respiratory symptoms for TB, post-TB lung disease, COPD, silicosis and pneumonia. All participants get a symptom check and a di…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Researchers examine rare Post-Transplant cancer to improve future care
Knowledge-focused OngoingThis study reviews medical records of 241 adults who developed a rare cancer called PTLD after an organ or stem cell transplant. Researchers aim to understand patient survival, disease features, and current treatments. No new treatments are tested; the goal is to gather informati…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC